var data={"title":"Hydromorphone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hydromorphone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6338?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hydromorphone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hydromorphone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=hydromorphone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hydromorphone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50847593\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada, in collaboration with manufacturers, will update the Canadian labelling of all prescription opioid products to include the following:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation for a daily opioid threshold dose for the management of chronic noncancer, nonpalliative pain (which aims to reduce risks of adverse events and overdoses associated with higher doses of opioids);</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation to limit the quantity of opioids prescribed for acute pain (which aims to reduce the duration of use and associated risks of developing dependence and substance use disorder); and</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Clarification of warnings, including those for special populations such as pregnant women and patients with a history of dependence or substance use disorder.</p></li></ul>\n        <p style=\"text-indent:0em;\">Health Canada has prioritized product tables for updating based on risk. The labelling updates for all prescription opioids are expected to be completed in January 2019.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65362a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708907\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Addiction, abuse, and misuse:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hydromorphone exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing hydromorphone and monitor all patients regularly for the development of these behaviors or conditions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening respiratory depression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, life-threatening, or fatal respiratory depression may occur with use of hydromorphone. Monitor for respiratory depression, especially during initiation of hydromorphone or following a dose increase. Instruct patients to swallow hydromorphone ER tablets whole; crushing, chewing, or dissolving hydromorphone ER can cause rapid release and absorption of a potentially fatal dose of hydromorphone.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Accidental ingestion:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Accidental ingestion of even one dose of hydromorphone, especially by children, can result in a fatal overdose of hydromorphone.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonatal withdrawal syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prolonged use of hydromorphone during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of medication errors:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">\n          <b>Injection:</b> High-potency hydromorphone (10 mg/mL) is a more concentrated solution of hydromorphone than hydromorphone 1, 2, or 4 mg/mL, and is for use in opioid-tolerant patients only. Do not confuse high-potency hydromorphone with standard parenteral formulations of hydromorphone or other opioids, as overdose and death could result.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n          <b>Oral solution:</b> Ensure accuracy when prescribing, dispensing, and administering hydromorphone oral solution. Dosing errors due to confusion between mg and mL can result in accidental overdose and death.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of hydromorphone and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180607\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dilaudid;</li>\n      <li>Dilaudid-HP [DSC];</li>\n      <li>Exalgo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180608\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Hydromorphone;</li>\n      <li>Dilaudid;</li>\n      <li>Dilaudid-HP;</li>\n      <li>Hydromorph Contin;</li>\n      <li>Hydromorphone HP;</li>\n      <li>Hydromorphone HP Forte Injection;</li>\n      <li>Hydromorphone Hydrochloride Injection USP HP 10;</li>\n      <li>Hydromorphone Hydrochloride Injection, USP;</li>\n      <li>Jurnista;</li>\n      <li>PMS-Hydromorphone;</li>\n      <li>Teva-Hydromorphone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180641\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Opioid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180611\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management:</b> <b>Note:</b> These are a guide and do not represent the maximum doses that may be required in all patients. Doses should be titrated to provide adequate pain relief. When changing routes of administration, oral doses and parenteral doses are <b>NOT</b> equivalent; parenteral doses are up to 5 times more potent. Therefore, when administered parenterally, one-fifth of the oral dose will provide similar analgesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral: Immediate release:</i> Initial: 2 to 4 mg every 4 to 6 hours as needed (tablets) or 2.5 mg to 10 mg every 3 to 6 hours as needed (oral solution); patients with prior opioid exposure may require higher initial doses. <b>Note:</b> An initial dose of 4 to 8 mg is recommended for severe pain (American Pain Society 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion from other opioids to hydromorphone oral immediate release: </i>Initial: 1 to 2 mg every 4 to 6 hours as needed (tablets) or 1.25 mg to 5 mg every 3 to 6 hours as needed (oral solution).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Discontinuation of therapy: </i>For patients on long-term opioid therapy, decrease dose by 25% to 50% every 2 to 4 days; monitor carefully for signs/symptoms of withdrawal. If patient displays withdrawal symptoms, increase dose to previous level and then reduce dose more slowly by increasing interval between dose reductions, decreasing amount of daily dose reduction, or both.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i> Initial: Opioid naive: 0.2 to 1 mg every 2 to 3 hours as needed; patients with prior opioid exposure may require higher initial doses. Hydromorphone HP should <b>NOT</b> be used in opioid-naive patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Critically ill patients (off-label dosing): 0.2 to 0.6 mg every 1 to 2 hours as needed <b>or</b> 0.5 mg every 3 hours as needed (Barr 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion: Usual dosage range: 0.5 to 3 mg/hour (Barr 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patient-controlled analgesia (PCA) (off-label dosing) (American Pain Society 2008):</i> <b>Note:</b> Opioid naive: Consider lower end of dosing range. A continuous (basal) infusion is not recommended in opioid-naive patients (ISMP 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual concentration: 0.2 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Demand dose: Usual initial dose: 0.2 mg; range: 0.05 to 0.4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lockout interval: 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Epidural PCA (off-label dosing) (de Leon-Casasola 1996; Liu 2010; Smith 2009):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual concentration: 0.01 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bolus dose: 0.4 to 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infusion rate: 0.03 to 0.3 mg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Demand dose: 0.02 to 0.05 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lockout interval: 10 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM, SubQ:</i> <b>Note:</b> IM use may result in variable absorption and lag time to peak effect; IM route not recommended for use (American Pain Society 2008). Equianalgesic doses: Morphine 10 mg IM = hydromorphone 1.5 mg IM.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>US labeling:</i> Initial: 1 to 2 mg every 2 to 3 hours as needed; lower initial doses may be used in opioid-naive patients. Patients with prior opioid exposure may require higher initial doses. Hydromorphone HP should <b>NOT</b> be used in opioid-naive patients.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from other opioids to hydromorphone injection</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Injection</i>: Convert the current total daily amount(s) of opioid(s) received to an equivalent total daily dose of hydromorphone injection and reduce by 50%. Divide the new total amount by the number of doses permitted based on dosing interval (eg, 8 doses for every 3 hour dosing). Titrate dose according to patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>HP injection:</i> Base the starting dose for hydromorphone HP injection on the prior dose of hydromorphone injection or on the prior dose of an alternate opioid.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Canadian labeling:</i> Opioid naive: 2 mg every 4 to 6 hours as needed; for severe pain, may administer 3 to 4 mg every 4 to 6 hours as needed. Hydromorphone HP or Hydromorphone HP Forte should <b>NOT</b> be used in opioid-naive patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Discontinuation of therapy</i>: For patients on long-term opioid therapy, decrease dose by 25% to 50% every 2 to 4 days; monitor carefully for signs/symptoms of withdrawal. If patient displays withdrawal symptoms, increase dose to previous level and then reduce dose more slowly by increasing interval between dose reductions, decreasing amount of daily dose reduction, or both.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Chronic pain:</b> <b>Note:</b> Patients taking opioids chronically may become tolerant and require doses higher than the usual dosage range to maintain the desired effect. Tolerance can be managed by appropriate dose titration. There is no optimal or maximal dose for hydromorphone in chronic pain. The appropriate dose is one that relieves pain throughout its dosing interval without causing unmanageable side effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Controlled-release capsule (Hydromorph Contin [Canadian product]):</i> Oral: <b>Note:</b> A patient's hydromorphone requirement should be established using prompt release formulations; conversion to long-acting products may be considered when chronic, continuous treatment is required. Higher dosages should be reserved for use only in opioid-tolerant patients. Capsule strengths &ge;18 mg or a single dose &gt;12 mg should be reserved for use only in opioid-tolerant patients requiring hydromorphone equivalent dosages &ge;36 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Opioid naive or receiving low intermittent doses of weak opioids: Initial: 3 mg every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Current therapy with other oral hydromorphone formulations: Initial: Initiate at same total daily hydromorphone dosage divided in 2 equal doses every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Current therapy with other opioids: Initial: Determine equivalent oral hydromorphone daily dosage and initiate in 2 equally divided doses every 12 hours. See table below for examples of equivalent dosing (refer to manufacturer labeling for additional equivalency dosing information).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Approximate Opioid Analgesic Equivalent Dosing (Oral)</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hydromorphone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Morphine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 mg (5 to 7.5 mg with chronic dosing of morphine)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Oxycodone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Codeine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">~27 mg</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended-release tablet (Exalgo):</i> <b>Note:</b> For use in opioid-tolerant patients only. Patients considered opioid tolerant are those who are receiving, for 1 week or longer, at least 60 mg of oral morphine daily, 25 mcg of transdermal fentanyl per hour, 30 mg of oral oxycodone daily, 8 mg of oral hydromorphone daily, 25 mg of oral oxymorphone daily, 60 mg oral hydrocodone daily, or an equianalgesic dose of another opioid.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Opioid-tolerant patients:</i> Discontinue or taper all other extended-release opioids when starting therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Individualization of dose:</i> Suggested recommendations for converting to hydromorphone ER from other analgesics are presented, but when selecting the initial dose, other characteristics (eg, patient status, degree of opioid tolerance, concurrent medications, type of pain, risk factors for addiction, abuse, and misuse) should also be considered. Pain relief and adverse events should be assessed frequently.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from other oral hydromorphone formulations to hydromorphone ER:</i> Start with the equivalent total daily dose of immediate-release hydromorphone administered once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from other opioids to hydromorphone ER:</i> Discontinue all other around-the-clock opioids when therapy is initiated. Substantial interpatient variability exists in relative potency. Therefore, it is safer to underestimate a patient&rsquo;s daily oral hydromorphone requirement and provide breakthrough pain relief with rescue medication (eg, immediate release opioid) than to overestimate requirements. In general, start hydromorphone ER at 50% of the calculated total daily dose every 24 hours (see Conversion Factors to hydromorphone ER). The following conversion ratios may be used to convert from oral opioid therapy to hydromorphone ER.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion factors to hydromorphone ER (see table):</i> Select the opioid, sum the current total daily dose, multiply by the conversion factor on the table to calculate the approximate oral hydromorphone daily dose, then calculate the approximate starting dose for hydromorphone ER at 50% of the calculated oral hydromorphone daily does; administer every 24 hours. Round down, if necessary, to the nearest strength available. For patients on a regimen of more than one opioid, calculate the approximate oral hydromorphone dose for each opioid and sum the totals to obtain the approximate total hydromorphone daily dose. For patients on a regimen of fixed-ratio opioid/nonopioid analgesic medications, only the opioid component of these medications should be used in the conversion. <b>Note:</b> The conversion factors in this conversion table are only to be used for the conversion from current oral opioid therapy to hydromorphone ER. Conversion factors in this table cannot be used to convert from hydromorphone ER to another oral opioid (doing so may lead to fatal overdose due to overestimation of the new opioid). This is not a table of equianalgesic doses.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Conversion Factors to Hydromorphone ER<sup>1</sup></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Previous Oral Opioid</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Oral Conversion Factor</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"2\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>The conversion factors are only to be used for the conversion from current opioid therapy to hydromorphone ER.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>2</sup>Monitor closely; ratio between methadone and other opioid agonists may vary widely as a function of previous drug exposure. Methadone has a long half-life and may accumulate in the plasma.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hydromorphone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Codeine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.06</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hydrocodone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.4</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Methadone<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.6</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Morphine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.2</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Oxycodone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.4</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Oxymorphone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.6</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:2em;\">\n      <i>Conversion from transdermal fentanyl to</i> <i>hydromorphone ER:</i> Treatment with hydromorphone ER can be started 18 hours after the removal of the transdermal fentanyl patch. For every fentanyl 25 mcg/hour transdermal dose, the equianalgesic dose of hydromorphone ER is 12 mg every 24 hours. An appropriate starting dose is 50% of the calculated total daily dose given every 24 hours. If necessary, round down to the appropriate tablet strength available.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:2em;\">\n      <i>Titration and maintenance:</i> Dose adjustments in 4 to 8 mg increments may occur every 3 to 4 days. In patients experiencing breakthrough pain, consider increasing the dose of hydromorphone ER or providing rescue medication of an immediate-release analgesic at an appropriate dose. Do not administer hydromorphone ER more frequently than every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:2em;\">\n      <i>Discontinuation of therapy:</i> For patients on long-term opioid therapy, decrease dose by 25% to 50% every 2 to 3 days; monitor carefully for signs/symptoms of withdrawal. If patient displays withdrawal symptoms, increase dose to previous level and then reduce dose more slowly by increasing interval between dose reductions, decreasing amount of daily dose reduction, or both.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Extended-release tablet: Jurnista [Canadian product]: <b>Note:</b> May be used in conjunction with usual doses of nonopioid analgesics and analgesic adjuvants. If appropriate, initiate therapy with an immediate-release opioid formulation to establish a safe and effective dosage, then convert to an equivalent daily dose of extended-release hydromorphone. Tablets &ge;16 mg are intended only for opioid-tolerant patients requiring hydromorphone equivalent dosages &ge;16 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">\n      <i>Initial:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:2em;\">Patients who are opioid naive or receiving low intermittent doses of weak opioid analgesics (eg, &lt; 40 mg daily oral morphine equivalents): Initial: 4 mg once daily (if clinically indicated, an initial dose of 8 mg once daily may be used; maximum initial dose: 8 mg once daily); titrate dose in increments of 4 or 8 mg as needed but no sooner than every fourth dose (eg, if first dose is administered on Tuesday, increase no sooner than on Friday).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:2em;\">Patients who are opioid naive or receiving low intermittent doses of weak opioid analgesics (eg, &lt;40 mg daily oral morphine equivalents): Initial: 4 mg once daily (if clinically indicated, an initial dose of 8 mg once daily may be used; maximum initial dose: 8 mg once daily); titrate dose in increments of 4 or 8 mg as needed but no sooner than every fourth dose (eg, if first dose is administered on Tuesday, increase no sooner than on Friday).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">\n      <i>Maintenance:</i> Dose is individualized based on response. May consider dose increases of 25% to 75% of current daily dose made no sooner than every 4th dose (eg, if first dose is administered on Tuesday, increase no sooner than on Friday). Reassess the need for around-the clock pain control periodically. Supplemental analgesia for breakthrough pain should typically not exceed 10% to 25% of the equivalent daily Jurnista dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">\n      <i>Discontinuation of therapy:</i> For patients on long-term opioid therapy, decrease dose by 50% every 2 days until lowest possible dose is reached and then discontinue. If patients displays withdrawal symptoms, increase dose slightly until signs of withdrawal are no longer present. May then resume taper but with longer periods of time between each dose reduction, or before switching to an equianalgesic dose of another opioid to continue tapering.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Moderate to severe pain:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Rectal:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>US labeling:</i> 3 mg (1 suppository) every 6 to 8 hours as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Canadian labeling:</i> 3 mg (1 suppository) at bedtime as needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180612\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Doses should be titrated to appropriate analgesic effects. When changing routes of administration, oral doses and parenteral doses are <b>NOT</b> equivalent; parenteral doses are up to 5 times more potent. Therefore, when administered parenterally, one-fifth of the oral dose will provide similar analgesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Pain management opioid-naive: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Use with caution; initiate at the low end of dosage range and titrate slowly. For patients &gt;70 years, the American Pain Society recommends consideration to lowering initial doses by 25% to 50% followed by upward or downward titration (APS 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, SubQ: Refer to adult dosing. Reduce initial doses as necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Reduce initial dose to 0.2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10169504\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injectable, oral (immediate release): Initiate with 25% to 50% of the usual starting dose depending on the degree of impairment. Use with caution and monitor closely for respiratory and CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral (extended-release tablet): Hydromorphone ER:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;40 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 40 to 60 mL/minute: Initiate with 50% of the usual starting dose for patients with normal renal function. Use with caution and monitor closely for respiratory and CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Initiate with 25% of the usual starting dose for patients with normal renal function. Use with caution and monitor closely for respiratory and CNS depression. Consider use of an alternate analgesic with better dosing flexibility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral (extended-release capsule): Hydromorph contin [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution and monitor closely for respiratory and CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate impairment: Initiate at 50% of initial dose for normal renal function; titrate cautiously. Monitor closely for respiratory and CNS depression following initiation of therapy and during titration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Initiate at 25% of initial dose for normal renal function; titrate cautiously. Monitor closely for respiratory and CNS depression following initiation of therapy and during titration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal suppository:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution and monitor closely for respiratory and CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, an initial dosage reduction is recommended for severe renal impairment. Use with caution and monitor closely for respiratory and CNS depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180613\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injectable, oral (immediate release): Mild to severe impairment:  Initiate with 25% to 50% of the usual starting dose depending on the degree of impairment. Use with caution and monitor closely for respiratory and CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral (extended-release tablet): Hydromorphone ER:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate impairment: Initiate with 25% of the usual starting dose for patients with normal hepatic function. Use with caution and monitor closely for respiratory and CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Use alternate analgesic.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral (extended-release capsule): Hydromorph contin [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution and monitor for respiratory and CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate impairment: Initiate at 25% of initial dose for normal hepatic function; titrate cautiously. Monitor closely for respiratory and CNS depression following initiation of therapy and during titration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Use is not recommended (has not been studied); consider alternative analgesics. If therapy with hydromorphone is initiated, the manufacturer recommends a more conservative dose than that recommended for moderate impairment but does not provide specific dosing recommendations. Monitor closely for respiratory and CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal suppository:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling: </i>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution and monitor closely for respiratory and CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, an initial dosage reduction is recommended for severe hepatic impairment. Use with caution and monitor closely for respiratory and CNS depression.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180578\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilaudid: 1 mg/mL (473 mL) [contains methylparaben, propylparaben, sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilaudid: 1 mg/mL (473 mL [DSC]) [contains methylparaben, propylparaben, sodium metabisulfite; sweet flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilaudid: 1 mg/mL (0.5 mL, 1 mL); 2 mg/mL (1 mL); 4 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilaudid-HP: 10 mg/mL (1 mL [DSC], 5 mL [DSC], 50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (0.5 mL, 1 mL); 2 mg/mL (1 mL, 20 mL); 4 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (1 mL); 50 mg/5 mL (5 mL); 500 mg/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/100 mL in NaCl 0.9% (50 mL, 100 mL [DSC]); 10 mg/50 mL in NaCl 0.9% (50 mL); 100 mg/100 mL (100 mL); 100 mg/50 mL in NaCl 0.9% (50 mL); 12 mg/30 mL in NaCl 0.9% (30 mL); 15 mg/30 mL in NaCl 0.9% (30 mL); 150 mg/150 mL in NaCl 0.9% (150 mL); 18 mg/30 mL in NaCl 0.9% (30 mL); 2 mg/50 mL in NaCl 0.9% (50 mL); 20 mg/100 mL in NaCl 0.9% (100 mL); 200 mg/100 mL in NaCl 0.9% (100 mL); 25 mg/250 mL in NaCl 0.9% (250 mL [DSC]); 25 mg/50 mL (50 mL); 250 mg/250 mL in NaCl 0.9% (250 mL); 30 mg/150 mL in NaCl 0.9% (150 mL); 30 mg/30 mL in NaCl 0.9% (30 mL); 36 mg/30 mL in NaCl 0.9% (30 mL); 40 mg/100 mL (100 mL); 40 mg/200 mL in NaCl 0.9% (200 mL); 5 mg/50 mL in NaCl 0.9% (50 mL); 50 mg/100 mL in NaCl 0.9% (100 mL); 50 mg/250 mL in NaCl 0.9% (250 mL); 50 mg/50 mL (50 mL); 6 mg/30 mL in NaCl 0.9% (30 mL); 60 mg/30 mL in NaCl 0.9% (30 mL); 62.5 mg/250 mL in NaCl 0.9% (250 mL [DSC]); 75 mg/250 mL in NaCl 0.9% (250 mL [DSC]); 9 mg/30 mL in NaCl 0.9% (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg/2 mL in NaCl 0.9% (2 mL); 0.5 mg/mL in NaCl 0.9% (1 mL); 1 mg/5 mL in NaCl 0.9% (5 mL); 1 mg/mL in NaCl 0.9% (1 mL); 10 mg/25 mL in NaCl 0.9% (25 mL); 12 mg/30 mL in NaCl 0.9% (30 mL); 12.5 mg/25 mL in NaCl 0.9% (25 mL); 15 mg/15 mL in NaCl 0.9% (15 mL [DSC]); 15 mg/30 mL in NaCl 0.9% (30 mL); 15 mg/50 mL in NaCl 0.9% (50 mL); 2 mg/10 mL in NaCl 0.9% (10 mL); 2.5 mg/25 mL in NaCl 0.9% (25 mL); 25 mg/25 mL in NaCl 0.9% (25 mL); 3 mg/30 mL in NaCl 0.9% (30 mL); 30 mg/30 mL in NaCl 0.9% (30 mL); 4 mg/mL in NaCl 0.9% (1 mL); 5 mg/25 mL in NaCl 0.9% (25 mL); 50 mg/50 mL in NaCl 0.9% (50 mL); 6 mg/30 mL in NaCl 0.9% (30 mL); 9 mg/45 mL in NaCl 0.9% (45 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilaudid-HP: 250 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suppository, Rectal, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3 mg (6 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilaudid: 2 mg, 4 mg [contains fd&amp;c yellow #10 aluminum lake, sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilaudid: 8 mg [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilaudid: 8 mg [DSC] [scored; contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg, 4 mg, 8 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet ER 24 Hour Abuse-Deterrent, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Exalgo: 8 mg, 12 mg, 16 mg, 32 mg [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 8 mg, 12 mg, 16 mg, 32 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180562\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950125\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, controlled release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hydromorph Contin: 3 mg, 4.5 mg, 6 mg, 9 mg, 12 mg, 18 mg, 24 mg, 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet extended release 24 Hour, Oral, as hydrochloride:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Jurnista: 4 mg, 8 mg, 16 mg, 32 mg (may contain traces of sodium metabisulfite)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180643\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10168465\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Exalgo: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM204267.pdf. Medication guides are also available at http://www.exalgorems.com.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Hydromorphone hydrochloride extended-release tablets:<a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM403064.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274gi/9/VJiH3c4GMxDLZytLNjg==&amp;TOPIC_ID=8538\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM403064.pdf</a>. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180582\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: <b>Note: Vial stopper may contain latex.</b> May be given SubQ or IM; IM route is not recommended (APS 2008). Hydromorphone HP (10 mg/mL) is a more concentrated solution of hydromorphone than hydromorphone 1, 2, or 4 mg/mL, and is for use in opioid-tolerant patients <b>only</b>. Do not confuse hydromorphone HP with standard parenteral formulations of hydromorphone or other opioids, as overdose and death could result.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: For IVP, must be given slowly over at least 2 to 3 minutes (rapid IVP has been associated with an increase in side effects, especially respiratory depression and hypotension)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Hydromorphone is available in an 8 mg immediate-release tablet and an 8 mg extended-release tablet. Extreme caution should be taken to avoid confusing dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hydromorphone ER, Jurnista [Canadian product]: Tablets should be swallowed whole; do not crush, break, chew, dissolve, snort, or inject. Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hydromorph Contin [Canadian product]: For oral use only. Capsule should be swallowed whole; do not crush or chew. Contents may be sprinkled on a tablespoon of applesauce (stored at room temperature or under refrigeration) or custard (stored at room temperature) and swallowed without chewing  as soon as possible (discard if not consumed within 30 minutes); patient should then rinse mouth with water to ensure entire contents are swallowed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution: Ensure accuracy when prescribing, dispensing, and administering. Dosing errors due to confusion between mg and mL can result in accidental overdose and death. A calibrated oral syringe/dosing cup that can measure and deliver the prescribed dose accurately should be used; do not use a household teaspoon or tablespoon to measure dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180581\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablet, oral solution, injection: Management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HP injection: Management of pain severe enough to require an opioid analgesic in opioid-tolerant patients who require higher doses of opioids and for which alternate treatments are inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release:</i> Management of pain in opioid-tolerant patients severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Reserve for use in patients for whom alternative treatment options (eg, nonopioid analgesics, opioid combination products) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Hydromorphone ER is not indicated as an as-needed analgesic.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Moderate to severe pain:</b> Suppository: Relief of moderate to severe pain such as that caused by biliary colic, burns, cancer, myocardial infarction, renal colic, surgery, and trauma (soft tissue and bone).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180651\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilaudid may be confused with Demerol, Dilantin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HYDROmorphone may be confused with morphine; significant overdoses have occurred when hydromorphone products have been inadvertently administered instead of morphine sulfate. Commercially available prefilled syringes of both products looks similar and are often stored in close proximity to each other. <b>Note:</b> Hydromorphone 1 mg oral is approximately equal to morphine 4 mg oral; hydromorphone 1 mg IV is approximately equal to morphine 5 mg IV</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilaudid, Dilaudid-HP: Extreme caution should be taken to avoid confusing the highly-concentrated (Dilaudid-HP) injection with the less-concentrated (Dilaudid) injectable product.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Exalgo: Extreme caution should be taken to avoid confusing the extended release Exalgo 8 mg tablets with immediate release hydromorphone 8 mg tablets.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180569\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, extrasystoles, flushing (facial), hypertension, hypotension, palpitations, peripheral edema, peripheral vasodilation, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, abnormal gait, abnormality in thinking, aggressive behavior, agitation, apprehension, ataxia, brain disease, burning sensation of skin (Exalgo), central nervous system depression, chills, cognitive dysfunction, confusion, decreased body temperature (Exalgo), depression, disruption of body temperature regulation (Exalgo), dizziness, drowsiness, drug dependence, dysarthria, dysphoria, equilibrium disturbance, euphoria, fatigue, hallucination, headache, hyperesthesia, hyperreflexia, hypoesthesia, hypothermia, increased intracranial pressure, insomnia, lack of concentration, lethargy, malaise, memory impairment, mood changes, myoclonus, nervousness, painful defecation, panic attack, paranoia, paresthesia, psychomotor agitation, restlessness, sedation, sleep disorder (Exalgo), suicidal ideation, uncontrolled crying, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, erythema (Exalgo), hyperhidrosis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Antidiuretic effect, decreased amylase, decreased libido, decreased plasma testosterone, dehydration, fluid retention, hyperuricemia, hypokalemia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, anal fissure, anorexia, bezoar formation (Exalgo), biliary tract spasm, constipation, decreased appetite, decreased gastrointestinal motility (Exalgo), delayed gastric emptying, diarrhea, diverticulitis, diverticulosis, duodenitis, dysgeusia, dysphagia, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease (aggravated; Exalgo), hematochezia, increased appetite, intestinal obstruction, intestinal perforation (large intestine; Exalgo), nausea, stomach cramps, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Bladder spasm, decreased urine output, difficulty in micturition, dysuria, erectile dysfunction, hypogonadism, sexual disorder, ureteral spasm, urinary frequency, urinary hesitancy, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Oxygen desaturation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Histamine release</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site, post-injection flare</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, dyskinesia, laryngospasm, muscle rigidity, muscle spasm, myalgia, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, diplopia, dry eye syndrome, miosis, nystagmus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, bronchospasm, dyspnea, flu-like symptoms (Exalgo), hyperventilation, hypoxia, respiratory depression, respiratory distress, rhinorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Angioedema, hypersensitivity, increased serum prolactin (Molitch 2008; Vuong 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180585\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>US labeling:</i></b> Hypersensitivity (eg, anaphylaxis) to hydromorphone, hydromorphone salts, or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment or ventilatory support; gastrointestinal obstruction, including paralytic ileus (known or suspected).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Additional product-specific contraindications:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dilaudid-HP injection: Opioid-nontolerant patients</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hydromorphone ER tablets: Opioid-nontolerant patients; preexisting GI surgery and/or diseases resulting in narrowing of GI tract or blind loops in the GI tract</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Suppository: Intracranial lesion associated with increased intracranial pressure; whenever ventilatory function is depressed (eg, COPD, cor pulmonale, emphysema, kyphoscoliosis, status asthmaticus).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for opioids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Canadian labeling:</i></b> Hypersensitivity to hydromorphone or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dilaudid, Hydromorph Contin, Jurnista: Known or suspected mechanical GI obstruction (eg, bowel obstruction or strictures) or any disease that affects bowel transit (eg, ileus of any type); suspected surgical abdomen (eg, acute appendicitis or pancreatitis); mild, intermittent, or short-duration pain that can be managed with other pain medications; acute respiratory depression, hypercarbia and cor pulmonale; acute alcoholism, delirium tremens, and convulsive disorders; severe CNS depression, increased cerebrospinal or intracranial pressure, and head injury; coadministration with monoamine oxidase inhibitors (concomitant use or within 14 days); women during pregnancy, labor and delivery, or breastfeeding</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dilaudid HP: Patients not already receiving high doses or high concentrations of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hydromorphone HP, Hydromorphone HP Forte: Patients not already receiving high doses or high concentrations of opioids; respiratory depression in the absence of resuscitative equipment; severe CNS depression; status asthmaticus; obstetrical analgesia; mild or moderate pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suppository, syrup: Respiratory depression in the absence of resuscitative equipment; status asthmaticus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Additional product-specific contraindications:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dilaudid: Hypersensitivity to other opioid analgesics; acute asthma or other obstructive airway and status asthmaticus</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hydromorph Contin: Hypersensitivity to other opioid analgesics; acute asthma or severe bronchial asthma or status asthmaticus; management of acute pain, including use in outpatient or day surgeries; management of perioperative pain</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Jurnista: Prior surgical procedures and/or underlying disease that may result in narrowing of the GI tract or have blind loops of the GI tract; acute asthma or other obstructive airway and status asthmaticus; management of acute or perioperative pain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180566\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Constipation: May cause constipation which may be problematic in patients with unstable angina and patients post-myocardial infarction. Consider preventive measures to reduce the potential for constipation. Use with extreme caution in patients with chronic constipation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute myocardial infarction [MI]), or drugs that may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenanthrene hypersensitivity: Use with caution in patients with  hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, levorphanol, oxycodone, oxymorphone).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: <b>[US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely for respiratory depression, especially during initiation or dose escalation. Swallow ER tablets whole; crushing, chewing, or dissolving can cause rapid release and a potentially fatal dose.</b> Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan, 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis; opioids may cause constriction of  sphincter of Oddi.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression/coma: Avoid use in patients with impaired consciousness or coma, as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delirium tremens: Use with caution in patients with delirium tremens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI narrowing: Hydromorphone ER tablets are nondeformable; do not administer to patients with preexisting severe GI narrowing (eg, esophageal motility, small bowel inflammatory disease, short gut syndrome, history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction, Meckel&rsquo;s diverticulum); obstruction may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reduction recommended in moderate to severe impairment. ER tablets are not recommended in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in patients who are morbidly obese.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Use with caution in patients with toxic psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended. ER tablets are not recommended in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease:  Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with a history of seizure disorders; may cause or exacerbate preexisting seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep-disordered breathing: Use opioids with caution for chronic pain and titrate dosage cautiously in patients with risk factors for sleep-disordered breathing, including HF and obesity. Avoid opioids in patients with moderate to severe sleep-disordered breathing (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzodiazepines or other CNS depressants: <b>[US Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of hydromorphone and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosage and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose. Use opioids for chronic pain with caution in this age group; monitor closely due to an increased potential for risks, including certain risks such as falls/fracture, cognitive impairment, and constipation. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increasing the risk for respiratory depression or overdose (Dowell [CDC 2016]). Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonatal withdrawal syndrome: <b>[US Boxed Warning]: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</b> Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release tablets: Therapy should only be prescribed by health care professionals familiar with the use of potent opioids for chronic pain. Tablets may be visible on abdominal x-rays, especially when digital enhancing techniques are used. The tablet shell may appear in the excreted stool.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral solution: <b>[US Boxed Warning]: Ensure accuracy when prescribing, dispensing, and administering hydromorphone oral solution. Dosing errors due to confusion between mg and mL can result in accidental overdose and death.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: <b>[US Boxed Warning]:</b> <b>High-potency hydromorphone (10 mg/mL) is a more concentrated solution of hydromorphone than hydromorphone 1, 2, or 4 mg/mL, and is for use in opioid-tolerant patients only. Do not confuse high-potency hydromorphone with standard parenteral formulations of hydromorphone or other opioids, as overdose and death could result. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Some formulations may contain lactose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Vial stoppers of single-dose injectable vials may contain latex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium metabisulfite: Some dosage forms may contain trace amounts of sodium metabisulfite, which may cause allergic reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion:<b> [US Boxed Warning]:</b> <b>Hydromorphone exposes patients and other users to the risks of addiction, abuse, and misuse, potentially leading to overdose and death. Assess each patient&rsquo;s risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions.</b> Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Other factors associated with increased risk for misuse include younger age, concomitant depression (major), and psychotropic medication use. Consider offering naloxone prescriptions in patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (&ge;50 morphine milligram equivalents/day orally), and concomitant benzodiazepine use (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental exposure: <b>[US Boxed Warning]: Accidental ingestion of even one dose, especially in children, can result in a fatal overdose of hydromorphone.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Chronic pain (outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder) in outpatient setting in adults: Opioids should <b>not</b> be used as first-line therapy for chronic pain management (pain &gt;3-month duration or beyond time of normal tissue healing) due to limited short-term benefits, undetermined long-term benefits, and association with serious risks (eg, overdose, MI, auto accidents, risk of developing opioid use disorder).  Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg. NSAIDs, acetaminophen, certain anticonvulsants and antidepressants). If opioid therapy is initiated, it should be combined with nonpharmacologic and nonopioid therapy, as appropriate. Prior to initiation, known risks of opioid therapy should be discussed and realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks.  Therapy should be initiated at the lowest effective dosage using immediate-release opioids (instead of extended-release/long-acting opioids). Risk associated with use increases with higher opioid dosages.  Risks and benefits should be re-evaluated when increasing dosage to &ge;50 morphine milligram equivalents (MME)/day orally; dosages &ge;90 MME/day orally should be avoided unless carefully justified (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IM administration: Variable absorption and a lag time to peak effect may result from IM use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Administer IV very slowly; rapid IV injection of opioid analgesics increases the possibility of side effects such as hypotension and respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Use immediate-release formulations with caution in the perioperative setting; severe pain may antagonize the respiratory depressant effects of hydromorphone. Opioids decrease bowel motility; monitor for decreased bowel motility in postop patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Concurrent use of mixed agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists.  Taper dose gradually when discontinuing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299481\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180571\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8538&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May enhance the analgesic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Opioid Analgesics. Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Opioid Analgesics may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of HYDROmorphone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: May diminish the therapeutic effect of Opioid Analgesics. Management: Avoid the concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics. If combined, larger doses of opioid analgesics will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids.  See full drug interaction monograph for detailed recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Analgesics. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Opioid Analgesics may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Opioid Analgesics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: May enhance the bradycardic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180588\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: Prolonged maternal use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If prolonged opioid therapy is required in a pregnant woman, ensure treatment is available and warn patient of risk to the neonate.</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Opioids cross the placenta. Maternal use of opioids may be associated with birth defects, poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2016]). If chronic opioid exposure occurs in pregnancy, adverse events in the newborn (including withdrawal) may occur (Chou 2009). Symptoms of neonatal abstinence syndrome (NAS) following opioid exposure may be autonomic (eg, fever, temperature instability), gastrointestinal (eg, diarrhea, vomiting, poor feeding/weight gain), or neurologic (eg, high-pitched crying, hyperactivity, increased muscle tone, increased wakefulness/abnormal sleep pattern, irritability, sneezing, seizure, tremor, yawning) (Dow 2012; Hudak 2012). Mothers who are physically dependent on opioids may give birth to Infants who are also physically dependent. Opioids may cause respiratory depression and psycho-physiologic effects in the neonate; newborns of mothers receiving opioids during labor should be monitored.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Agents other than hydromorphone are commonly used to treat maternal pain during labor and immediately postpartum (ACOG 177 2017) as well as chronic noncancer pain in pregnant women or those who may become pregnant (CDC [Dowell 2016]; Chou 2009; Kahan 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180589\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Hydromorphone is present in breast milk (Edwards 2003).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The half-life of hydromorphone was 10.5 &plusmn; 5.2 hours in breast milk following a single intranasal dose of hydromorphone 2 mg (Edwards 2003).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Current guidelines note that nonopioid analgesics are preferred for postpartum pain in breastfeeding women (Montgomery 2012). When opioids are needed in breastfeeding women, the lowest effective dose for the shortest duration of time should be used to limit adverse events in the mother and breastfeeding infant; use of hydromorphone may be considered. Delivery by PCA will help limit infant exposure (Sachs 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, a single, occasional dose of an opioid analgesic may be generally compatible with breastfeeding (WHO 2002). [<b>Note:</b> Extended release formulations are not indicated for intermittent pain control]. Breastfeeding women using opioids for postpartum pain or for the treatment of chronic maternal pain should monitor their infants for drowsiness, sedation, feeding difficulties, or limpness (ACOG 177 2017; Montgomery 2012; Sachs 2013). Withdrawal symptoms may occur when maternal use is discontinued or breastfeeding is stopped.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180575\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pain relief, respiratory and mental status, blood pressure; signs of misuse, abuse, and addiction; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate recommendations: Chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder): Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. Re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Urine drug testing is recommended prior to initiation and re-checking should be considered at least yearly (includes controlled prescription medications and illicit drugs of abuse). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (Dowell [CDC 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180565\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to opioid receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; causes cough suppression by direct central action in the medulla; produces generalized CNS depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180584\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Analgesic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate-release formulations: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: 15 to 30 minutes; Peak effect: 30 to 60 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 5 minutes; Peak effect: 10 to 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release tablet: 6 hours; Peak effect: ~9 hours (Angst 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate-release formulations: Oral, IV: 3 to 4 hours; suppository may provide longer duration of effect </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release tablet: ~13 hours (Angst 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapidly absorbed; extensive first-pass effect; Extended-release tablet: Delayed; IM: Variable and delayed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 4 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~8% to 19% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via glucuronidation; to inactive metabolites; &gt;95% is metabolized to hydromorphone-3-glucuronide; minor amounts as 6-hydroxy reduction metabolites  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral, immediate release: ~24%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate-release formulations: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release tablets: Apparent half-life: ~11 hours (range: 8 to 15 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate-release tablet: &le;1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release tablet: 12 to 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release capsule [Canadian product]: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (primarily as glucuronide conjugates); minimal unchanged drug is excreted in urine (~7%) and feces (1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5989385\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Dilaudid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (473 mL): $490.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (HYDROmorphone HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (473 mL): $189.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dilaudid Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (0.5 mL): $3.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (1 mL): $4.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $4.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (HYDROmorphone HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $3.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (1 mL): $3.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $3.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (HYDROmorphone HCl PF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1 mL): $3.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (HYDROmorphone HCl-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/50 mL 0.9% (50 mL): $15.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3MG/30ML 0.9% (30 mL): $28.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/50 mL 0.9% (50 mL): $15.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6MG/30ML 0.9% (30 mL): $24.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9MG/30ML 0.9% (30 mL): $24.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/100 mL 0.9% (50 mL): $12.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/50 mL 0.9% (50 mL): $14.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12MG/30ML 0.9% (30 mL): $27.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15MG/30ML 0.9% (30 mL): $28.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18MG/30ML 0.9% (30 mL): $28.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/100 mL 0.9% (100 mL): $18.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">24MG/30ML 0.9% (30 mL): $25.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/50 mL 0.9% (50 mL): $19.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25MG/250ML 0.9% (250 mL): $32.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30MG/150ML 0.9% (150 mL): $19.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30MG/30ML 0.9% (30 mL): $30.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">36MG/30ML 0.9% (30 mL): $34.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/100 mL 0.9% (100 mL): $23.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/200 mL 0.9% (200 mL): $21.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/100 mL 0.9% (100 mL): $25.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/50 mL 0.9% (50 mL): $20.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MG/250ML 0.9% (250 mL): $22.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60MG/30ML 0.9% (30 mL): $43.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $35.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/50 mL 0.9% (50 mL): $32.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150MG/150ML 0.9% (150 mL): $43.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/100 mL 0.9% (100 mL): $55.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250MG/250ML 0.9% (250 mL): $83.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (HYDROmorphone HCl-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4MG/2ML 0.9% (2 mL): $5.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/mL 0.9% (1 mL): $5.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL 0.9% (1 mL): $5.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1MG/5ML 0.9% (5 mL): $5.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2MG/10ML 0.9% (10 mL): $5.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5MG/25ML 0.9% (25 mL): $12.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3MG/30ML 0.9% (30 mL): $12.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL 0.9% (1 mL): $7.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5MG/25ML 0.9% (25 mL): $11.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6MG/30ML 0.9% (30 mL): $12.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/50 mL 0.9% (50 mL): $10.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10MG/25ML 0.9% (25 mL): $10.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12MG/30ML 0.9% (30 mL): $15.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12MG/60ML 0.9% (60 mL): $14.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5MG/25ML 0.9% (25 mL): $13.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/50 mL 0.9% (50 mL): $15.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15MG/30ML 0.9% (30 mL): $13.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/50 mL 0.9% (50 mL): $15.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/50 mL 0.9% (50 mL): $14.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25MG/25ML 0.9% (25 mL): $15.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30MG/30ML 0.9% (30 mL): $17.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/50 mL 0.9% (50 mL): $16.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">55MG/55ML 0.9% (55 mL): $24.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (HYDROmorphone HCl Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (6): $73.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet ER 24 Hour Abuse-Deterrent</b> (Exalgo Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (100): $1,673.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg (100): $2,510.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16 mg (100): $3,346.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">32 mg (100): $6,693.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet ER 24 Hour Abuse-Deterrent</b> (HYDROmorphone HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (100): $1,353.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg (100): $2,030.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16 mg (100): $2,707.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">32 mg (100): $3,840.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Dilaudid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $239.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $390.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (100): $711.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (HYDROmorphone HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $42.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $63.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (100): $132.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180590\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dilaudid (AT, AU, BB);</li>\n      <li>Dilid (KR);</li>\n      <li>Dolonovag (AR);</li>\n      <li>Himop (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Hydal (AT);</li>\n      <li>Jurnista (AT, AU, CR, CZ, DE, DK, DO, EE, ES, GT, HN, HU, ID, IT, MX, NI, NZ, PA, PH, PT, SA, SG, SI, SV, ZW);</li>\n      <li>Jurnista IR (KR);</li>\n      <li>Jurnista SR (KR);</li>\n      <li>Liberaxim (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Narurapid (JP);</li>\n      <li>Narusus (JP);</li>\n      <li>Paliadon Retardkaps (DE);</li>\n      <li>Palladon (CH, DK, FI, IS, NL, NO, SE, SI);</li>\n      <li>Palladon OD (SE);</li>\n      <li>Palladon Retard (CH);</li>\n      <li>Palladone (BE, CZ, EE, ES, GB, GR, HN, IE, IL, LU, PT);</li>\n      <li>Palladone SR (GB, SK);</li>\n      <li>Palladone-SR (HU);</li>\n      <li>Sophidone LP (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists Number 36, July 2002. Obstetric Analgesia and Anesthesia,&quot; <i>Obstet Gynecol</i>, 2002, 100(1):177-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/12100826/pubmed\" target=\"_blank\" id=\"12100826\">12100826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Agency for Health Care Policy and Research, &ldquo;Acute Pain Management in Infants, Children and Adolescents: Operative and Medical Procedures,&rdquo; <i>Am Fam Physician</i>, 1992, 46(2):469-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/1636563/pubmed\" target=\"_blank\" id=\"1636563\">1636563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins&mdash;Obstetrics. Practice bulletin no. 177: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2017 129(4):e73-e89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/28333819/pubmed\" target=\"_blank\" id=\"28333819\">28333819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Angst MS, Drover DR, Lotsch J, et al, &ldquo;Pharmacodynamics of Orally Administered Sustained-release Hydromorphone in Humans,&rdquo; <i>Anesthesiology</i>, 2001, 94(1):63-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/11135723/pubmed\" target=\"_blank\" id=\"11135723\">11135723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/23414717/pubmed\" target=\"_blank\" id=\"23414717\">23414717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou R, Fanciullo GJ, Fine PG, et al, &quot;Clinical Guidelines For the Use of Chronic Opioid Therapy in Chronic Noncancer Pain,&quot;<i> J Pain</i>, 2009, 10(2):113-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/19187889/pubmed\" target=\"_blank\" id=\"19187889\">19187889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Leon-Casasola OA and Lema MJ, &quot;Postoperative Epidural Opioid Analgesia: What Are the Choices?&quot; <i>Anesth Analg</i>, 1996, 83(4):867-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/8831337/pubmed\" target=\"_blank\" id=\"8831337\">8831337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dilaudid (hydroxymorphone) [prescribing information]. Stamford, CT: Purdue Pharma; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dilaudid , Dilaudid-HP (hydromorphone) [prescribing information]. Stamford, CT: Purdue Pharma; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dilaudid (hydromorphone) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dilaudid-HP (hydromorphone) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dow K, Ordean A, Murphy-Oikonen J, et al, &quot;Neonatal Abstinence Syndrome Clinical Practice Guidelines For Ontario,&quot; <i>J Popul Ther Clin Pharmacol</i>, 2012, 19(3):e488-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/23241498/pubmed\" target=\"_blank\" id=\"23241498\">23241498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain&mdash;United States, 2016. <i>MMWR Recomm Rep</i>. 2016;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/26987082/pubmed\" target=\"_blank\" id=\"26987082\">26987082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Pain,&rdquo; <i>Med Lett Drugs Ther</i>, 2000, 42(1085):73-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/10951654/pubmed\" target=\"_blank\" id=\"10951654\">10951654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards JE, Rudy AC, Wermeling DP, Desai N, McNamara PJ. Hydromorphone transfer into breast milk after intranasal administration. <i>Pharmacotherapy</i>. 2003;23(2):153-158.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/12587803/pubmed\" target=\"_blank\" id=\"12587803\">12587803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Exalgo (hydroxymorphone) [prescribing information]. Webster Groves, MO: Mallinckrodt Brand Pharma; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferrell BA, &ldquo;Pain Management in Elderly People,&rdquo; <i>J Am Geriatr Soc</i>, 1991, 39(1):64-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/1670940/pubmed\" target=\"_blank\" id=\"1670940\">1670940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Honigberg IL, and Stewart JT, &ldquo;Radioimmunoassay of Hydromorphone and Hydrocodone in Human Plasma,&rdquo; <i>J Pharm Sci</i>, 1980, 69(10):1171-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/6158568/pubmed\" target=\"_blank\" id=\"6158568\">6158568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hudak ML, Tan RC, Committee On Drugs, et al, &quot;Neonatal Drug Withdrawal,&quot; <i>Pediatrics</i>, 2012, 129(2):e540-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/22291123/pubmed\" target=\"_blank\" id=\"22291123\">22291123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hydromorphone hydrochloride (potency injection) [prescribing information]. Lake Forest, IL: Hospira Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hydromorphone hydrochloride suppositories (prescribing information). Minneapolis, MN: Perrigo; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hydromorph Contin (hydromorphone) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hydromorphone HP (hydromorphone) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; April 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP). Beware of basal opioid infusions with PCA therapy. https://www.ismp.org/Newsletters/acutecare/articles/20090312.asp. 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inturrisi CE, &ldquo;Narcotic Drugs,&rdquo; <i>Med Clin North Am</i>, 1982, 66(5):1061-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/6127453/pubmed\" target=\"_blank\" id=\"6127453\">6127453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jurnista (hydromorphone) [product monograph]. Markham, Ontario, Canada: Janssen Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A; National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. <i>Can Fam Physician.</i> 2011;57(11):1269-1276.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/22084456/pubmed\" target=\"_blank\" id=\"22084456\">22084456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaiko RF, Wallenstein SL, Rogers AG, et al, &ldquo;Narcotics in the Elderly,&rdquo; <i>Med Clin North Am</i>, 1982, 66(5):1079-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/7132470/pubmed\" target=\"_blank\" id=\"7132470\">7132470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy MH, &ldquo;Pharmacologic Treatment of Cancer Pain,&rdquo; <i>N Engl J Med</i>, 1996, 335(15):1124-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/8813044/pubmed\" target=\"_blank\" id=\"8813044\">8813044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu SS, Bieltz M, Wukovits B, et al, &quot;Prospective Survey of Patient-Controlled Epidural Analgesia With Bupivacaine and Hydromorphone in 3736 Postoperative Orthopedic Patients,&quot; <i>Reg Anesth Pain Med</i>, 2010, 35(4):351-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/20607876/pubmed\" target=\"_blank\" id=\"20607876\">20607876</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lugo RD and Kern SE, &ldquo;Pharmacokinetics of Opioids,&rdquo; <i>Management of Pain</i>, Lipman AG ed, Bethesda, MD: ASHP, 2004, 77.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molitch ME. Drugs and prolactin. <i>Pituitary</i>. 2008;11(2):209-218. doi: 10.1007/s11102-008-0106-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/18404390/pubmed\" target=\"_blank\" id=\"18404390\">18404390</a>]</span><span class=\"doi\">10.1007/s11102-008-0106-6</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, and Academy of Breastfeeding Medicine, &quot;ABM Clinical Protocol #15: Analgesia and Anesthesia For the Breastfeeding Mother, Revised 2012,&quot; <i>Breastfeed Med</i>, 2012, 7(6):547-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nasraway SA Jr, &ldquo;Use of Sedative Medications in the Intensive Care Unit,&rdquo; <i>Sem Resp Crit Care Med</i>, 2001, 22(2):165-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/16088671/pubmed\" target=\"_blank\" id=\"16088671\">16088671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pms-Hydromorphone (hydromorphone) [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc; February 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith HS, <i>Current Therapy in Pain</i>, 1st ed, Philadelphia, PA: Saunders, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. <i>Endocr Rev</i>. 2010;31(1):98-132. doi: 10.1210/er.2009-0009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/19903933/pubmed\" target=\"_blank\" id=\"19903933\">19903933</a>]</span><span class=\"doi\">10.1210/er.2009-0009</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo; <i>Ann Pharmacother</i>, 2004, 38:1525-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydromorphone-drug-information/abstract-text/15252190/pubmed\" target=\"_blank\" id=\"15252190\">15252190</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8538 Version 262.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50847593\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708907\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F180607\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F180608\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F180641\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F180611\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F180612\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F10169504\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F180613\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F180578\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F180562\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950125\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F180643\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10168465\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F180582\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F180581\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F180651\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F180569\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F180585\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F180566\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299481\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F180571\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F180588\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F180589\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F180575\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F180565\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F180584\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5989385\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F180590\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8538|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hydromorphone-patient-drug-information\" class=\"drug drug_patient\">Hydromorphone: Patient drug information</a></li><li><a href=\"topic.htm?path=hydromorphone-pediatric-drug-information\" class=\"drug drug_pediatric\">Hydromorphone: Pediatric drug information</a></li></ul></div></div>","javascript":null}